HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Gets $91 Million Boost, Sequestered User Fees In 2014 Appropriation

This article was originally published in The Rose Sheet

Executive Summary

A 2014 omnibus appropriations bill agreed to by Senate and House appropriators would give FDA $2.55 billion in discretionary funding, a $91 million increase. The bill would also make available $85 million in previously sequestered FDA user fees.

You may also be interested in...



FDA Seeks $19 Mil. From Cosmetics Firms In User-Fee-Heavy 2014 Budget

Collecting user fees from cosmetics manufacturers to the tune of $19 million would help “improve FDA’s capacity to promote greater safety and understanding of cosmetic products,” the agency says. FDA submitted a similar proposal last year and will be up against challenges again in securing the necessary legislation.

Food Safety User Fees On Hold Until FDA Creates Waiver Process

Dietary supplement and food product firms will not incur user fees for facility or import re-inspections or mandatory recalls until FDA establishes a waiver process for small businesses.

Performance Issues With CDC’s COVID-19 Assay Reagent Slows Rollout Of Test Kits To US States

A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.

UsernamePublicRestriction

Register

RS019225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel